CBD Life Sciences Inc. (CBDL) Announces Groundbreaking 100MG Full Spectrum CBD Gummy Geared Toward Mental Health & Focus
Rhea-AI Summary
CBD Life Sciences Inc. (OTC:CBDL) has launched a groundbreaking 100MG Full Spectrum CBD Gummy targeting mental health and focus. The product, available in Crisp Green Apple and Wild Blueberry flavors, is positioned as a natural alternative for mental clarity and emotional well-being.
The launch comes as the global CBD market is projected to exceed $60 billion by 2030, with the mental wellness industry surpassing $500 billion. The company's CEO, Lisa Nelson, emphasizes this product's role in addressing mental health challenges without pharmaceutical side effects.
Key features include:
- Lab-tested formulation with verified Certificates of Analysis (COAs)
- Full-spectrum cannabinoids for enhanced effectiveness
- Target audience includes entrepreneurs, creatives, students, and professionals
The company is currently in preliminary discussions with wellness clinics and mental health centers for potential integration into patient routines, though no formal agreements have been established.
Positive
- Strategic positioning in two rapidly growing markets
- High-potency product differentiation with 100MG dosage
- Lab-verified quality with available COAs
- Potential partnerships with wellness clinics and mental health centers
Negative
- No formal agreements yet with healthcare facilities
- Highly competitive CBD market space
- Premium pricing potential due to high CBD content
News Market Reaction
On the day this news was published, CBDL declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
With the global CBD market expected to exceed
SCOTTSDALE, AZ / ACCESS Newswire / April 22, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) a leader in cannabinoid-driven health innovation - proudly announces the launch of its most anticipated product to date: a high-dosage 100MG Full Spectrum CBD Gummy, meticulously formulated to support mental health, daily focus, and emotional well-being.
Available in mouth-watering Crisp Green Apple and Wild Blueberry flavors, this isn't your average CBD gummy. It's a next-generation wellness tool - designed not only to relax the body but to sharpen the mind. Crafted with full-spectrum cannabinoids, these gummies are being positioned as a natural ally in the pursuit of mental clarity, balance, and daily productivity.
"Mental health isn't a trend - it's a global crisis. And people are tired of band-aid solutions," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This product was built to empower people who want to feel better and function better - without the side effects of traditional pharmaceuticals. It's a powerful, natural alternative that speaks directly to the stress, anxiety, and attention struggles millions face every day."
Lab tested and verified with Certificates of Analysis (COAs), this 100MG gummy represents the company's deepest push yet into the lucrative mental wellness category. Unlike many low-dose competitors, CBDL's bold formulation is made for people who need real results - entrepreneurs, creatives, students, parents, and professionals looking to stay in control of their mood and mindset.
Early conversations with several wellness clinics and mental health centers are already in progress, exploring how this high-potency gummy could be integrated into patient routines. While no formal agreements have been made, the demand is clear: health professionals are actively seeking natural, high-quality, lab-verified CBD options to complement modern mental wellness protocols.
CBDL is rapidly building a portfolio that taps into high-value niches: from pain relief and nano-enhanced beverages to functional CBD coffee creamers and now, this cutting-edge product for mental clarity. The company's ability to stay ahead of trends and deliver results has attracted attention from both investors and the wellness industry.
"We're not trying to follow the market - we're reshaping it," Nelson added. "With this launch, we're doubling down on our belief that the future of wellness lies in functional, focused, and effective cannabinoid products."
This release is a bold statement to shareholders and the industry: CBD Life Sciences Inc. is serious about mental health. The company's momentum continues to build, and with this new launch, they're inviting wellness professionals, retail buyers, and everyday users to experience the next level of what CBD can offer.
The 100MG Mental Health Gummies are available now, with full lab reports and wholesale interest forms available on the company's website.
For product information, COAs, or wholesale inquiries, please visit www.thecbdvault.com.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (CBDL) is a leading innovator in the wellness and alternative health sector, specializing in high-quality CBD and functional mushroom products designed to enhance well-being. With a commitment to scientific research and consumer safety, CBDL continues to push the boundaries of holistic health solutions, creating opportunities for exponential growth in a rapidly evolving market.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What makes CBDL's new 100MG CBD gummy different from competitors?
How is CBDL positioning itself in the CBD and mental wellness markets?
What distribution channels is CBDL exploring for its new mental health gummies?
What is the target market for CBDL's new 100MG CBD gummies?
Where can customers verify the lab testing results for CBDL's new CBD gummies?
